Baudax Bio is a pharmaceutical company primarily focused on developing and commercializing products for hospital and related acute care settings. Co.'s commercial product, ANJESO, is for the management of moderate to severe pain, alone or in combination with other non-nonsteroidal anti-inflammatory drugs analgesics. ANJESO is a once a day, preferential COX-2 inhibitor that possesses analgesic, anti-inflammatory, and antipyretic activities. Co.'s pipeline also includes other earlier stage product candidates including intermediate and short-acting neuromuscular blocking agents, and accompanying reversal agents, DEX-IN, along with other product candidates. The BXRX stock yearly return is shown above.
The yearly return on the BXRX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the BXRX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|